

# Featured Stock in April's Dividend Growth Model Portfolio

Nine new stocks make our <u>Dividend Growth Stocks Model Portfolio</u> this month, which was made available to members on April 29, 2021.

### **Recap From March's Picks**

On a price return basis, our Dividend Growth Stocks Model Portfolio (+1.9%) underperformed the S&P 500 (+5.4%) by 3.5% from March 26, 2021 through April 27, 2021. On a total return basis, the Model Portfolio (+2.1%) underperformed the S&P 500 (+5.4%) by 3.3% over the same time. The best performing stock was up 19%. Overall, 8 out of the 30 Dividend Growth Stocks outperformed the S&P 500 from March 26, 2021 through April 27, 2021.

Learn more about the best fundamental research

More reliable & <u>proprietary</u> fundamental data, proven in <u>The Journal of Financial Economics</u>, drives our research. Our proprietary <u>Robo-Analyst technology</u><sup>1</sup> scales our forensic accounting expertise (<u>featured in</u> <u>Barron's</u>) across thousands of stocks<sup>2</sup> to produce an unrivaled database of fundamental data.

The methodology for this model portfolio mimics an All-Cap Blend style with a focus on dividend growth. Selected stocks earn an <u>Attractive or Very Attractive rating</u>, generate positive free cash flow (<u>FCF</u>) and <u>economic</u> <u>earnings</u>, offer a current dividend yield >1%, and have a 5+ year track record of consecutive dividend growth. This model portfolio is designed for investors who are more focused on long-term capital appreciation than current income, but still appreciate the power of dividends, especially growing dividends.

### Featured Stock From April: Johnson & Johnson (JNJ: \$168/share)

Johnson & Johnson (JNJ) is the featured stock from April's Dividend Growth Stocks Model Portfolio.

We originally made Johnson & Johnson a Long Idea in February 2020 and reiterated it in January 2021. Despite underperforming the S&P 500, JNJ remains undervalued.


Johnson & Johnson has grown revenue and net operating profit after-tax (<u>NOPAT</u>) by 3% compounded annually over the past 10 years. The firm's trailing-twelve-month NOPAT margin sits at 21%, which also equals the company's average margin since 2010.

<sup>&</sup>lt;sup>1</sup> Harvard Business School features our research automation technology in the case <u>Disrupting Fundamental Analysis with Robo-Analysts</u>.

<sup>&</sup>lt;sup>2</sup> See how our models and financial ratios are superior to Bloomberg and Capital IQ's (SPGI) analytics in the detailed appendix of this paper.








Sources: New Constructs, LLC and company filings

### Steady Dividend Growth Supported by FCF

Johnson & Johnson has increased its regular dividend in every year for the last 59 years and from \$0.97/share in 1998 to \$4.04/share in 2020, or 7% compounded annually. The current guarterly dividend, when annualized, equals \$4.24/share and provides a 2.4% dividend yield.

More importantly, Johnson & Johnson's strong free cash flow (FCF) supports the firm's growing dividend payments. Johnson & Johnson generated a cumulative \$47.7 billion (11% of current market cap) in FCF while paying \$47.5 billion in dividends from 2016 to 2020, per Figure 2. In the TTM period, Johnson & Johnson generated \$14.5 billion in FCF and paid \$10.6 billion in dividends.



Sources: New Constructs, LLC and company filings

Companies with FCF well in excess of dividend payments provide higher guality dividend growth opportunities because we know the firm generates the cash to support a higher dividend. On the other hand, the dividend of a company where FCF falls short of the dividend payment over time cannot be trusted to grow or even maintain its dividend because of inadequate free cash flow.



### JNJ Has Upside Potential

At its current price of \$168/share, JNJ has a price-to-economic book value (<u>PEBV</u>) ratio of 0.9. This ratio means the market expects Johnson & Johnson's NOPAT to permanently decline by 10%. This expectation seems overly pessimistic for a firm that has grown NOPAT by 7% compounded annually over the past two decades.

Even if Johnson & Johnson's NOPAT margin falls to its 20-year low of 17% (compared to 21% in 2020) and the firm grows NOPAT by just 3% compounded annually for the next decade, the stock is worth \$219/share today – a 30% upside. See the math behind the reverse DCF scenario. Add in Johnson & Johnson's 2.4% dividend yield and history of dividend growth, and it's clear why this stock is in April's Dividend Growth Stocks Model Portfolio.

### Critical Details Found in Financial Filings by Our Robo-Analyst Technology

Fact: we provide <u>superior fundamental data</u> and earnings models – unrivaled in the world. Proof: <u>Core Earnings: New Data and Evidence</u>, forthcoming in The Journal of Financial Economics.

Below are specifics on the adjustments we make based on Robo-Analyst findings in Johnson & Johnson's filings:

Income Statement: we made \$5.2 billion in adjustments with a net effect of removing \$2.5 billion in <u>non-operating</u> <u>expenses</u> (3% of revenue). See all adjustments made to Johnson & Johnson's income statement <u>here</u>.

Balance Sheet: we made \$87.9 billion of adjustments to calculate invested capital with a net increase of \$9.2 billion. The most notable adjustment was \$15.2 billion (12% of reported net assets) in <u>other comprehensive</u> income. See all adjustments to Johnson & Johnson's balance sheet <u>here</u>.

Valuation: we made \$76.2 billion in adjustments with a net effect of decreasing shareholder value by \$30.4 billion. Apart from <u>total debt</u>, one of the most notable adjustments to shareholder value was \$22.9 billion in <u>excess cash</u>. This adjustment represents 5% of Johnson & Johnson's market value. See all adjustments to Johnson & Johnson's valuation <u>here</u>.

This article originally published on May 7, 2021.

Disclosure: David Trainer, Kyle Guske II, Alex Sword, and Matt Shuler receive no compensation to write about any specific stock, style, or theme.

Follow us on Twitter, Facebook, LinkedIn, and StockTwits for real-time alerts on all our research.



## It's Official: We Offer the Best Fundamental Data in the World

Many firms claim their research is superior, but none of them can prove it with independent studies from highlyrespected institutions as we can. Three different papers from both the public and private sectors show:

- 1. Legacy fundamental datasets suffer from significant inaccuracies, omissions and biases.
- 2. Only our "novel database" can overcome these flaws and provides <u>materially superior</u> fundamental data.
- 3. Our proprietary measures of <u>Core Earnings</u> and <u>Earnings Distortion</u> materially improve stock picking and forecasting of profits.

### Best Fundamental Data in the World

Forthcoming in <u>The Journal of Financial Economics</u>, a top peer-reviewed journal, <u>Core Earnings: New Data &</u> <u>Evidence</u> proves our Robo-Analyst technology overcomes material shortcomings in legacy firms' data collection processes to provide superior <u>fundamental data</u>, <u>earnings</u> models, and <u>research</u>. More <u>details</u>.

Key quotes from the paper:

- "[New Constructs'] Total Adjustments differs significantly from the items identified and excluded from Compustat's adjusted earnings measures. For example... 50% to 70% of the variation in Total Adjustments is not explained by S&P Global's (SPGI) Adjustments individually." – pp. 14, 1<sup>st</sup> para.
- "A final source of differences [between New Constructs' and S&P Global's data] is due to data collection oversights...we identified cases where Compustat did not collect information relating to firms' income that is useful in assessing core earnings." – pp. 16, 2<sup>nd</sup> para.

#### **Superior Models**

A top accounting firm features the superiority of our ROIC, NOPAT and Invested Capital research to Capital IQ & Bloomberg's in <u>Getting ROIC Right</u>. See the <u>Appendix</u> for direct comparison details.

Key quotes from the paper:

- "...an accurate calculation of ROIC requires more diligence than often occurs in some of the common, off-the-shelf ROIC calculations. Only by scouring the footnotes and the MD&A [ as New Constructs does] can investors get an accurate calculation of ROIC." – pp. 8, 5<sup>th</sup> para.
- "The majority of the difference...comes from New Constructs' machine learning approach, which leverages technology to calculate ROIC by applying accounting adjustments that may be buried deeply in the footnotes across thousands of companies." – pp. 4, 2<sup>nd</sup> para.

#### **Superior Stock Ratings**

Robo-Analysts' stock ratings outperform those from human analysts as shown in this <u>paper</u> from Indiana's Kelley School of Business. Bloomberg features the paper <u>here</u>.

Key quotes from the paper:

- "the portfolios formed following the buy recommendations of Robo-Analysts earn abnormal returns that are statistically and economically significant." pp. 6, 3<sup>rd</sup> para.
- "Our results ultimately suggest that Robo-Analysts are a valuable, alternative information intermediary to traditional sell-side analysts." pp. 20, 3<sup>rd</sup> para.

Our mission is to provide the best fundamental analysis of public and private businesses in the world and make it affordable for all investors, not just Wall Street insiders.

We believe every investor deserves to know the whole truth about the profitability and valuation of any company they consider for investment. More details on our cutting-edge technology and how we use it are <u>here</u>.



### DISCLOSURES

New Constructs®, LLC (together with any subsidiaries and/or affiliates, "New Constructs") is an independent organization with no management ties to the companies it covers. None of the members of New Constructs' management team or the management team of any New Constructs' affiliate holds a seat on the Board of Directors of any of the companies New Constructs covers. New Constructs does not perform any investment or merchant banking functions and does not operate a trading desk.

New Constructs' Stock Ownership Policy prevents any of its employees or managers from engaging in Insider Trading and restricts any trading whereby an employee may exploit inside information regarding our stock research. In addition, employees and managers of the company are bound by a code of ethics that restricts them from purchasing or selling a security that they know or should have known was under consideration for inclusion in a New Constructs report nor may they purchase or sell a security for the first two days after New Constructs issues a report on that security.

### **DISCLAIMERS**

The information and opinions presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or solicitation of an offer to buy or sell securities or other financial instruments. New Constructs has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor and nothing in this report constitutes investment, legal, accounting or tax advice. This report includes general information that does not take into account your individual circumstance, financial situation or needs, nor does it represent a personal recommendation to you. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about any such investments or investment services.

Information and opinions presented in this report have been obtained or derived from sources believed by New Constructs to be reliable, but New Constructs makes no representation as to their accuracy, authority, usefulness, reliability, timeliness or completeness. New Constructs accepts no liability for loss arising from the use of the information presented in this report, and New Constructs makes no warranty as to results that may be obtained from the information presented in this report. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information and opinions contained in this report reflect a judgment at its original date of publication by New Constructs and are subject to change without notice. New Constructs may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and New Constructs is under no obligation to insure that such other reports are brought to the attention of any recipient of this report.

New Constructs' reports are intended for distribution to its professional and institutional investor customers. Recipients who are not professionals or institutional investor customers of New Constructs should seek the advice of their independent financial advisor prior to making any investment decision or for any necessary explanation of its contents.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would be subject New Constructs to any registration or licensing requirement within such jurisdiction.

This report may provide the addresses of websites. Except to the extent to which the report refers to New Constructs own website material, New Constructs has not reviewed the linked site and takes no responsibility for the content therein. Such address or hyperlink (including addresses or hyperlinks to New Constructs own website material) is provided solely for your convenience and the information and content of the linked site do not in any way form part of this report. Accessing such websites or following such hyperlink through this report shall be at your own risk.

All material in this report is the property of, and under copyright, of New Constructs. None of the contents, nor any copy of it, may be altered in any way, copied, or distributed or transmitted to any other party without the prior express written consent of New Constructs. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of New Constructs. LLC 2003 through the present date. All rights reserved.